After reaching an important support level, Xilio Therapeutics, Inc. (XLO) could be a good stock pick from a technical perspective. XLO recently experienced a "golden cross" event, which saw its 50-day ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Fintel reports that on May 30, 2023, Chardan Capital reiterated coverage of Xilio Therapeutics (NASDAQ:XLO) with a Buy recommendation. As of May 11, 2023, the average one-year price target for Xilio ...

Xilio Therapeutics, Inc. (NASDAQ:XLO) announced promising updated Phase 2 results for its investigational therapy vilastobart, combined with atezolizumab, in heavily pre-treated patients with ...

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...